A federal court granted Amgen a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., as well as upheld a jury verdict regarding certain patent-infringement claims.     Mircera is currently available in Europe and the FDA has approved the drug, but the legal dispute prevented its sale. The drug, if released in the U.S., would compete directly with Amgen’s anemia drugs Aranesp and Epogen, which accounted for more than 40% of its revenue...